First-line treatment for prostate cancer and use of antidepressants

According to a recently reported study in the journal European Urology, men who received first-line surgery or radiation therapy for non-metastatic prostate cancer were significantly more likely to have taken an antidepressant 5 years later than comparable men who didn’t get such treatment. … READ MORE …

Understanding “cell-free DNA analysis” in cancer diagnosis and management

We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …

Did you get an MRI scan as part of your clinical work-up for prostate cancer risk?

A report in the journal Urology (the so-called “Gold Journal”) from a team of researchers at Yale School of Medicine has shown that having a prostate MRI as part of the work-up for a patient initially diagnosed with low-risk prostate cancer roughly doubled the chance that such a patient was initially managed on “observation”. … READ MORE …

Improving survival among men with oligorecurrent prostate cancer?

A newly published article in the Journal of Clinical Oncology reports data from a small, randomized, multicenter, Phase II clinical trial comparing active monitoring to treatment of men with recurrent, asymptomatic, oligometastatic prostate cancer. … READ MORE …

Serial mpMRIs instead of serial biopsies for men on active surveillance

The role of baseline and repeat multiparametric MRI (mpMRI) scanning as a substitute for repeat biopsies in the initial evaluation and ongoing management of men on active surveillance continues to evolve. … READ MORE …

The role of 3 T mpMRI in monitoring men on active surveillance

A newly published paper in the American Journal of Roetgenology provides an early data set on the application of 3 T multiparameric MRI scans in monitoring men on active surveillance (as opposed to the use of serial biopsies). … READ MORE …

The initial (10-year) results of the ProtecT trial: much as we might have expected?

So the majority of the readers of The “New” Prostate Cancer InfoLink will be well aware that we have never had data from a large, randomized clinical trial comparing the outcomes of the commonest first-line forms of management of men diagnosed with localized prostate cancer … READ MORE …